Growth hormone provocative test of 5 036 cases in pediatric clinic: a single center nursing
10.3760/cma.j.issn.1672-7088.2019.35.005
- VernacularTitle: 单中心门诊5 036例儿童生长激素激发试验的护理
- Author:
Xiaohua HE
1
;
Huamei MA
;
Siqin LI
;
Liyan HE
Author Information
1. Department of Pediatrics, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China
- Publication Type:Clinical Trail
- Keywords:
Growth hormone provocative test;
Levodopa;
Pyridostigmine;
Nursing care
- From:
Chinese Journal of Practical Nursing
2019;35(35):2741-2745
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the nursing experience of growth hormone provocative test in pediatric clinic.
Methods:Five thousand and thirty-six children with short stature or slowing growth received combined simultaneous Levodopa Pyridostigmine stimulation test from June 2008 to October 2018 in the Child Growth Center of the First Affiliated Hospital of SUN Yat-sen University. Comprehensive nursing intervention was conducted to ensure the test carry through successfully before, during and after the test.
Results:All children completed the five collections in the 120-minute growth hormone provocative test without cannula obstruction and blurt out. Some (986 out of 5 036 children, 19.58%) had different degrees of adverse reactions including nausea, vomiting, abdominal pain, sweating, salivation, dizziness, pallor, etc., most of which disappeared or alleviated after nursing, except 11 patients (0.22%) needed atropine muscular injection and 3 of whom needed intravenous fluids to release the marked symptoms.
Conclusion:Combined simultaneous Levodopa Pyridostigmine stimulation test is safe and practicable in pediatric clinics with nursing experience.
